Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Neurocrine: 4Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
02/04/2020 | 04:56pm EDT

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported fourth-quarter profit of $34 million.

On a per-share basis, the San Diego-based company said it had profit of 35 cents.

The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 82 cents per share.

The biopharmaceutical company posted revenue of $244.1 million in the period, exceeding Street forecasts. Four analysts surveyed by Zacks expected $242.4 million.

For the year, the company reported profit of $37 million, or 39 cents per share. Revenue was reported as $788.1 million.

Neurocrine shares have dropped 4% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $103.10, a climb of 17% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NEUROCRINE BIOSCIENCES, IN
05/26NEUROCRINE BIOSCIENCES : to Present at the Jefferies Virtual Healthcare Conferen..
PR
05/21NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submissi..
AQ
05/14NEUROCRINE BIOSCIENCES : to Present at the RBC Capital Markets 2020 Global Healt..
PR
05/14NEUROCRINE BIOSCIENCES : to Present Data from its Movement Disorder Portfolio on..
AQ
05/06NEUROCRINE BIOSCIENCES : Management's Discussion and Analysis of Financial Condi..
AQ
05/06NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Fina..
AQ
05/06NEUROCRINE : 1Q Earnings Snapshot
AQ
05/06NEUROCRINE BIOSCIENCES : Reports First Quarter 2020 Financial Results
PR
05/05NEUROCRINE BIOSCIENCES : to Present at Bank of America Merrill Lynch Health Care..
PR
04/27NEUROCRINE BIOSCIENCES : Announces FDA Approval of Once-Daily ONGENTYS® (opicapo..
PU
More news
Financials (USD)
Sales 2020 1 077 M
EBIT 2020 388 M
Net income 2020 306 M
Finance 2020 794 M
Yield 2020 -
P/E ratio 2020 38,0x
P/E ratio 2021 25,1x
EV / Sales2020 9,51x
EV / Sales2021 7,11x
Capitalization 11 041 M
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 121,33 $
Last Close Price 118,89 $
Spread / Highest target 16,9%
Spread / Average Target 2,06%
Spread / Lowest Target -15,0%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.16.10%11 041
GILEAD SCIENCES12.62%91 795
VERTEX PHARMACEUTICALS21.72%69 097
REGENERON PHARMACEUTICALS45.20%60 715
WUXI APPTEC CO., LTD.18.87%25 297
GENMAB A/S41.82%20 190